Policy Analysts: DEA's Emergency 7-OH Scheduling Is Scientifically Unjustified, Could Harm Opioid Users

Why it matters

The DEA's emergency scheduling of 7-OH could criminalize products used by millions of Americans managing chronic pain and opioid use disorder, potentially pushing them back to more dangerous illicit opioids. Policy analysts argue the data cited in the DEA's own notice does not support claims of an imminent public threat warranting Schedule I classification.

The big picture

The DEA filed its Notice of Intent on July 1, 2026, to temporarily place 7-hydroxymitragynine (7-OH) and three related compounds into Schedule I. The notice cited 85 overdose cases involving 7-OH since 2019, 55 of them fatal — a figure analysts argue is negligible relative to an estimated hundreds of millions of doses consumed annually in a market worth billions. NIH has simultaneously funded research into mitragynine as a potential OUD treatment, creating tension between enforcement timelines and ongoing scientific inquiry.

Key findings

• DEA documented just 85 overdose cases involving 7-OH since 2019, 55 fatal — nearly all involving other substances like fentanyl
• Annual U.S. 7-OH sales estimated in the billions of dollars, implying an extremely low death rate relative to consumption volume
• Naloxone appears effective at reversing 7-OH respiratory effects, as with other opioid compounds
• NIH has already funded research into mitragynine for opioid use disorder treatment; Schedule I status would obstruct that work
• Over 40% of surveyed kratom users report using it as a long-term opioid replacement, with reported continuous abstinence at 6 and 12 months

What they say

A Schedule I designation would penalize consumers who are trying to reduce their risks by using a less harmful alternative to opioids, likely pushing many back toward potentially adulterated opioids, and stymieing the research needed to demonstrate kratom's potential as a therapy. — Reason.org policy analysis

Bottom line

The DEA's emergency 7-OH scheduling rests on 85 cases over seven years in a market worth billions, raising serious questions about proportionality and the cost to millions who rely on it as a safer opioid alternative.